<DOC>
	<DOCNO>NCT02361294</DOCNO>
	<brief_summary>The study design evaluate role platelet immature platelet ethiopathology deep venous thrombosis pulmonary embolism .</brief_summary>
	<brief_title>Immature Plateletes Etiopathology Deep Venous Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>Patients newly diagnose deep venous thrombosis and/or pulmonary embolism . The thrombembolism idiopathic cause immobilisation . Control : Patients present suspicion deep venous thrombosis exclude duplex sonography . therapy glycoprotein IIb/IIIaantagonists within last 10 day therapy antiplatelet drug ( ASA , Clopidogrel , Ticagrelor , Prasugrel , Dipyridamol ) preexist anticoagulation number platelet &lt; 100.000/µl anemia ( hematocrit &lt; 35 % , Hb &lt; 10 g/dl ) age &gt; 80 &lt; 18 renal insufficiency GFR &lt; 30 ml/min hepatic impairment increase risk bleeding coagulopathy , liver cirrhosis ( ≥ Child Pugh B ) intracranial intracerebral bleeding within last six month intraspinal intracerebral vascular anomaly clinically relevant acute bleeding malign disease infection within last 7 hematological , rheumatologic autoimmune disease operation within last six month transfusion rec celll concentrate within last six month transfusion fresh frozen plasma platelet concentrate within last month preexist medication CYP 3A4 inhibitor inductor , pglycoprotein inhibitor ( AzolAntimycotis , HIV proteaseinhibitors ) hypersensitivity/contraindications Rivaroxaban pregnancy lactation thrombophilia thrombocytopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>